New cocktail aims to tame Immunotherapy's worst side effects in melanoma

NCT ID NCT03999749

First seen Mar 28, 2026 · Last updated May 14, 2026 · Updated 4 times

Summary

This study tests whether adding the drug tocilizumab to the standard immunotherapy combination of ipilimumab and nivolumab can reduce serious immune-related side effects in people with advanced melanoma that cannot be removed by surgery. About 71 participants will receive the three drugs together for 12 weeks, followed by maintenance nivolumab alone for up to a year. The goal is to see if this approach makes the treatment safer while still controlling the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • NYU Langone Health

    New York, New York, 10016, United States

  • The Angeles Clinic

    Los Angeles, California, 90025, United States

Conditions

Explore the condition pages connected to this study.